Psychedelic Drugs: Types, Uses, and Effects

Research from 2016 assessed the use of psilocybin in helping 15 individuals quit smoking. The findings indicated that two moderate doses of 200 micrograms decreased anxiety, with these effects persisting throughout a 12-month follow-up period. The results suggested that psilocybin produced a substantial and long lasting reduction in depression and anxiety, as well as increases in optimism and quality of life.

Why do people use psychedelic and dissociative drugs?

Additionally, a 2016 clinical trial explored the effects of psilocybin on the symptoms of depression and anxiety in 51 individuals with a diagnosis of potentially life threatening cancer. Research from 2016 investigated the effects of psilocybin on 12 people with treatment-resistant depression. A 2021 study describes psychedelics as serotonergic hallucinogens, which are agonists of serotonergic 5-HT2A receptors. Therapists and psychiatrists can recommend evidence-based treatments safer than drugs that come with risks when consumed. If you want something to help with mental health issues or just to help you cope, consider talking to a professional before trying psychedelics.

Are psychedelic and dissociative drugs addictive? Can people experience withdrawal?

Repeated drug use can lead to brain changes that make self-control more challenging. Another long-term effect is a phenomenon called hallucinogen persisting perception disorder (HPPD). Dependence refers to a physical reliance on a drug, whereas addiction refers to a behavioral change arising from a compulsion to continue taking a drug. There’s no treatment for HPPD, but research suggests certain medications may be effective. A 26-year-old woman who attended the same party accidentally took around 500 micrograms of LSD but didn’t require medical intervention.15

Instead, psychedelics hold the potential to guide individuals on journeys of self-discovery, healing, and personal growth. While substances like LSD may produce tolerance, they do not induce the compulsive drug-seeking behaviors characteristic of addictive substances. Examples of psychedelics include LSD (lysergic acid diethylamide), psilocybin (found in magic mushrooms), DMT (dimethyltryptamine), and mescaline (found in peyote cacti). Psychedelics, a term coined by British psychiatrist Humphry Osmond, encompass a broad category of substances known for their mind-altering effects.

“I can say that while psychedelics helped me to stop using substances, I’d like to reflect that these aren’t a cure,” said Guckel, a founder of a company that offers psychedelic-assisted recovery. Now a professional recovery coach, Guckel said psychedelics might hold a promise to treat addiction disorders. Learn more about psychedelic and dissociative drugs and their legal status in the United States from the DEA. Information on the use of psychedelic and dissociative drugs is collected by several national surveys. Some organizations are using harm reduction practices to help avoid drug overdose deaths related to possible adulteration of certain psychedelic and dissociative drugs, particularly those taken in pill, powder, or liquid form.15 This means adulteration of psychedelic and dissociative drugs with fentanyl and similar compounds is possible, but more research is needed to understand to what extent this occurs.

What Are the Types of Hallucinogens?

Among other health effects, dissociative drugs can also alter people’s perception of reality. While more research is needed, the reported incidence of serious adverse events from professionally supervised use of specific psychedelic and dissociative drugs, such as in clinical trials, is relatively low.2,10,11,26 However, many past clinical studies on these drugs have not adequately assessed or reported on adverse events.27 Although research is ongoing, studies suggest psychedelic drugs—such as psilocybin, LSD, and DMT—primarily affect 5-HT2A receptors in the brain, which ordinarily are activated by the neurotransmitter (chemical messenger) serotonin.10 NIDA supports and conducts research on the short- and long-term health effects of psychedelic and dissociative drugs to better inform health decisions and policies related to their use. Psychedelic drugs (also called “classic psychedelics” or “psychedelics”), including psilocybin and LSD, mainly interact with specific receptors, which are molecular structures in the brain.

• The journey to hallucinogen addiction often begins with recreational use, escalating as users chase euphoria or escape reality.
• Hallucinogen dependence is a separate category to HUD, based on generic substance use dependence criteria, several of which do not apply to hallucinogens.
• But the enthusiasm for psilocybin and ibogaine for treating substance-use conditions has been gradually increasing.
• Instead, psychedelics hold the potential to guide individuals on journeys of self-discovery, healing, and personal growth.
• In non-clinical settings, there have been rare cases of psychedelics triggering psychotic episodes (e.g. Dos Santos et al., 2017; Tapia et al., 2021).
• Similarly, administration of LSD results in high acute drug liking ratings but no craving (Holze et al., 2021; Schmid et al., 2015).

For example, Kendler et al. (1999) provide a 0.2% estimate of hallucinogen dependence among hallucinogen-using female twins. HUD is relatively uncommon, with a low risk of development following exposure to hallucinogens (Shalit et al., 2019). Withdrawal symptoms and signs are not established for hallucinogens, and so this criterion is not included.

How many young students use hallucinogens**?

Around 17 percent of Americans have met criteria for a substance use disorder in the past year, said Stephanie Tabashneck, the event’s moderator. That is, until he tried psychedelic plants, such as ayahuasca, psilocybin, and ibogaine. Despite numerous attempts to overcome his substance use disorder, nothing helped. NIDA is a biomedical research organization and does not provide personalized medical advice, treatment, counseling, or legal consultation. However, the legal status of some of these drugs is evolving. These surveys use the terms “hallucinogen” and “hallucinogen use disorder” and data from those surveys are reported below.

Psychological and psychiatric risks

There is a wide variety of hallucinogenic mushrooms, and their legal status is somewhat ambiguous, as they can be found growing wild in many parts of the world. Like mescaline, ololiuqui has a long history of use in spiritual rituals among indigenous groups where the plant grows but unlike mescaline, it is not a controlled substance in the U.S. Ololiuqui is a naturally occurring psychedelic that is found in the seeds of the morning glory flower, which grows in Central and South America. The effects of mescaline are similar to those of LSD.

Cross-tolerance to other substances can also occur. This can be risky due to the unpredictable effects that the drug may have. Ololiuqui’s effects are similar to those of LSD, but the drug may also cause nausea, vomiting, headache, high blood pressure, and drowsiness. Psilocybin is a psychedelic is alcoholism a mental illness substance found in certain fungi, sometimes referred to as magic mushrooms. Mescaline is a naturally occurring psychedelic substance found in certain species of cactus, the most well-known being the peyote cactus.

• Some psychedelic and dissociative drugs are also synthetic (lab-made).2 People report using psychedelic and dissociative drugs for a variety of reasons, including seeking new, fun, healing, or spiritual experiences.1,3
• Earlier studies sometimes neglected the importance of set and setting, contributing to the risk of adverse effects occurring (e.g. Malitz et al., 1960; Rinkel et al., 1960) and did not include the stringent control conditions or groups that are standard in today’s clinical psychopharmacology research (Johnson et al., 2008).
• Several hallucinogens exist, including synthetic drugs like LSD and natural psychedelics like shrooms.
• Psychedelics, a term coined by British psychiatrist Humphry Osmond, encompass a broad category of substances known for their mind-altering effects.
• Among people aged 12 or older in 2021, 2.6% (or about 7.4 million people) reported using hallucinogens in the past 12 months.

Reduce depression and anxiety

NIDA conducts and supports research on psychedelic and dissociative drugs to help inform policies and health decisions around their use. The bottom line is that psychedelics are drugs that can be very dangerous if a person uses them without proper medical guidance. The goal is to help users stop using drugs and develop healthy coping methods.

The effects of psychedelic drugs vary depending on the person. Psychedelic drugs are a group of substances that change or enhance sensory perceptions, thought processes, and energy levels. Despite all the craze around psychedelics, little research has been done to prove their efficacy treating addiction disorders. Last year, Oregon opened a state-regulated program for supervised administration of psilocybin, and next year, Colorado will open a similar program for psilocybin and possibly ibogaine to be used as a treatment for addiction under medical supervision, he said.

By measuring these factors, they created a data-driven index that classified substances according to their relative risk. One of the most comprehensive efforts to assess the relative safety of various drugs was led by Professor David Nutt and published in The Lancet in 2010. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Dive deeper into the realm of psychedelics with us, and let curiosity be your guide.

Unlike stimulants, opioids, and alcohol, psychedelics do not create physical dependence or trigger the same compulsive drug-seeking behaviors seen in addictive substances. Such benefits are part of why psychedelics are being investigated not only for mental health treatments but also for their potential to promote overall brain health. Unlike addictive substances such as opioids, which target the brain’s reward system and induce compulsive drug-seeking behavior, psychedelics tread a different path. These substances are also known as hallucinogenic drugs or simply hallucinogens. Accounts like Guckel’s and the idea that psychedelics might prompt a neurochemical reset in the brain have many looking to the approach as a promising treatment for addiction disorders. Drug Enforcement Administration (DEA) lists most psychedelic and dissociative drugs on the U.S. schedule of controlled substances.

More studies are needed to better understand how psychedelic and dissociative drugs work. For more information, see “How do psychedelic and dissociative drugs work in the brain? Other drugs such as MDMA, ibogaine, and salvia work on a variety of brain functions to cause psychedelic or dissociative effects.

This narrative review examines the evidence for potential harms of the classic psychedelics by separating anecdotes and misinformation from systematic research. Studies to date have not found evidence that classic psychedelics, such as psilocybin, LSD, and mescaline, cause neurotoxicity. Neurotoxic substances can kill brain cells, cause permanent cognitive damage, or alter the function of neurotransmitters in ways that may lead to long-term psychological harm. One of the most notable findings from Nutt’s study is that psychedelics such as psilocybin and LSD have a low physical toxicity profile. Nutt and his team evaluated drugs based on multiple dimensions, including physical harm, dependence, and social harm. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Several hallucinogens exist, including synthetic drugs like LSD and natural psychedelics like shrooms. Early studies showed that drugs commonly accepted as having hallucinogenic properties are not self-administered by laboratory animals (the gold standard test for dependence potential) supporting their low dependence in humans (see detailed analysis by Griffiths et al., 1979). Johnson et al. (2018) reviewed the abuse potential of medical psilocybin according to the eight factors of the controlled substances act, highlighting its limited reinforcing effects. In Anthony et al.’s (1994) classic study on problematic drug use, based on representative data from the US National Comorbidity Survey, psychedelics had the lowest rate of abuse from all drugs analysed of users who qualified for a dependence diagnosis (4.9%). In summary, psychedelics, particularly psilocybin, demonstrate low physical toxicity, no apparent neurotoxic effects, and minimal addiction potential. These findings suggest that certain psychedelics may not only lack addiction potential themselves but may also serve as powerful tools in combating addiction to other, more harmful substances.